talimogene laherparepvec

💊Medication

Generic name

Talimogene Laherparepvec

Brand names

Imlygic

Drug class

Antineoplastic cell and gene therapy

Active ingredients

herpesvirus 1, human

Route

Intralesional

Dosage form

Injection

Type

Human Prescription Drug

Manufacturer

Amgen Inc

Indications: 1 INDICATIONS AND USAGE IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve over… (per FDA label)

• Talimogene Laherparepvec in Non-Melanoma Cancers.The Journal of clinical and aesthetic dermatology · 2021
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
• Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.Frontiers in molecular biosciences · 2022
• Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.Journal for immunotherapy of cancer · 2019
• Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.Current oncology reports · 2024

via PubMed

• EARLY_PHASE1COMPLETED
  Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerSOLTI Breast Cancer Research Group · NCT03802604
• PHASE2COMPLETED
  Study of TVEC in Patients With Cutaneous Squamous Cell CancerUniversity of Arizona · NCT03714828
• PHASE1/PHASE2COMPLETED
  TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)Royal Marsden NHS Foundation Trust · NCT03555032
• PHASE2TERMINATED
  Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by SurgeryM.D. Anderson Cancer Center · NCT02658812
• COMPLETED
  Registry Study for Talimogene LaherparepvecAmgen · NCT02173171
• PHASE1TERMINATED
  Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the SkinRutgers, The State University of New Jersey · NCT04163952

via ClinicalTrials.gov

Wikidata facts

Instance of

medication

Subclass of

virus

Image

Herpes simplex virus TEM B82-0474 lores.jpg

via Wikidata · CC0